Trimethylamine N-oxide and prognosis in acute heart failure
Trimethylamine N-oxide and prognosis in acute heart failure
复制标题
DOI：
10.1136/heartjnl-2015-308826
复制
发表时间：
2016-06-01
期刊：
影响因子：
5.7
通讯作者：
Ng, Leong L.
中科院分区：
文献类型：
--
作者：
Suzuki, Toru;Heaney, Liam M.;Ng, Leong L.
目的急性心力衰竭（AHF）是一种高病死率和高致残率的疾病。氧化三甲胺（TMAO）是一种肠源性代谢物，已报道与慢性HF的死亡风险相关，但AHF中的这种相关性仍然未知。本研究调查TMAO在AHF患者入院，并与预后的循环水平，共972血浆样本进行了分析，通过液相色谱-质谱法的TMAO浓度。与住院死亡率的关系（72起事件），全因死亡（死亡，268起事件）和因HF死亡或再次住院的复合终点结果TMAO结合当前临床评分改善了住院死亡率的危险分层（OR >= 1.13，p = 1.61，p = 2.15，p = 1.16，p = 0.001）。
Objective Acute heart failure (AHF) is associated with high mortality and morbidity. Trimethylamine N-oxide (TMAO), a gut-derived metabolite, has reported association with mortality risk in chronic HF but this association in AHF is still unknown. The present study investigated TMAO in patients admitted to hospital with AHF, and association of circulating levels with prognosis.Methods In total, 972 plasma samples were analysed for TMAO concentration by liquid chromatography-mass spectrometry. Associations with in-hospital mortality (72 events), all-cause mortality (death, 268 events) and a composite of death or rehospitalisation due to HF (death/HF, 384 events) at 1 year were examined.Results TMAO improved risk stratification for in-hospital mortality in combination with current clinical scorings (OR >= 1.13, p = 1.61, p = 2.15, p = 1.16, p